CIPROFLOXACIN OPHTHALMIC SOLUTION, USP, 0.3% as base, Sterile

/CIPROFLOXACIN OPHTHALMIC SOLUTION, USP, 0.3% as base, Sterile
CIPROFLOXACIN OPHTHALMIC SOLUTION, USP, 0.3% as base, Sterile2018-09-06T09:12:40+00:00

Prescription Drug Name:

CIPROFLOXACIN OPHTHALMIC SOLUTION, USP, 0.3% as base, Sterile

ID:

15bd7469-0b0f-4479-a86e-dad3b7694ec6

Code:

34391-3

DESCRIPTION


id: 81477f38-1ce2-4197-be8e-d195530e09e0
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Ciprofloxacin Ophthalmic Solution, USP is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid. It is a faint to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C17H18FN3O3•HCl•H2O and its chemical structure is as follows: Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position. Each mL of Ciprofloxacin Ophthalmic Solution, USP contains:
Active: Ciprofloxacin HCl, USP 3.5 mg equivalent to 3 mg base.
Preservative: Benzalkonium Chloride 0.006%.
Inactives: Acetic Acid, Edetate Disodium 0.05%, Mannitol 4.6%, Sodium Acetate, Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH) and Water for Injection. The pH is approximately 4.5 and the osmolality is approximately 300 mOsm.

INDICATIONS AND USAGE


id: 20390627-57cd-4367-b9a3-afeedec6b3ce
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Ciprofloxacin Ophthalmic Solution, USP is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:

Corneal Ulcers: Pseudomonas aeruginosa
Serratia marcescensEfficacy for this organism was studied in fewer than 10 infections.
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Streptococcus (Viridans Group)
Conjunctivitis: Haemophilus Influenzae
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae

CONTRAINDICATIONS


id: 07501049-907b-4c80-bdd4-503fc10e92d7
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

WARNINGS


id: 12051828-3146-4767-b20e-b2603a5c35b4
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

NOT FOR INJECTION INTO THE EYE. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. Remove contact lenses before using.

ADVERSE REACTIONS


id: 18ff5f54-58a2-4a6f-9104-76c5f0ab2442
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

The most frequently reported drug related adverse reaction was local burning or discomfort. In corneal ulcer studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients (see PRECAUTIONS ). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and a bad taste following instillation. Additional events occurring in less than 1% of patients included corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision.

OVERDOSAGE


id: f6027d05-fdef-493c-b74e-b23cce82e6e7
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

A topical overdose of Ciprofloxacin Ophthalmic Solution, USP may be flushed from the eye(s) with warm tap water.

HOW SUPPLIED


id: 2a3963ac-3c08-4c4e-ad5b-41f2d411d1a3
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

As a sterile ophthalmic solution: 2.5 mL, 5 mL and 10 mL in white opaque plastic dropper bottles.

2.5 mL
5 mL 55700-245-05
10 mL

ANIMAL PHARMACOLOGY


id: 3390ddfa-63d3-4cb4-ba15-534ee742d09f
displayName: ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION
FDA Article Code: 34091-9

Ciprofloxacin and related drugs have been shown to cause arthropathy in immature animals of most species tested following oral administration. However, a one-month topical ocular study using immature Beagle dogs did not demonstrate any articular lesions.